GATA3 INHIBITORS FOR THE TREATMENT OF TYPE-2 DIABETES AND INSULIN RESISTANCE AND PROMOTION OF SUBCUTANEOUS FAT DEPOSITION

摘要

Methods and compositions using dnayzme-based GATA3 inhibitors for the treatment of insulin resistance and Type II diabetes, for the stimulation of adipogenesis in vivo, and for the promotion of fat redistribution are disclosed.